ALACHUA, Fla. (APRIL 21, 2014) – RTI Surgical Inc. (RTI) (Nasdaq: RTIX), a leading global surgical implant company, announced today the full market launch of the Streamline® OCT System. The system is designed to promote fusion of the occipto-cervico-thoracic spine (or occiput-T3). RTI received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the system in March 2014.

Read the full story.